Infusystem Hld Stock Price, News & Analysis

InfuSystem Holdings (NYSE American: INFU) and Sanara MedTech have announced an exclusive U.S. distribution agreement with ChemoMouthpiece, Their joint venture, SI Healthcare Technologies, will distribute ChemoMouthpiece's FDA-cleared oral cryotherapy device to approximately 3,000 cancer centers through InfuSystem's Oncology sales team.

The device aims to reduce oral mucositis in patients undergoing chemotherapy. Sanara invested $5 million for a 6.6% ownership in ChemoMouthpiece. The U.S. market for oral mucositis treatment is estimated at over $600 million annually, affecting 500,000 to 1 million patients. The American Medical Association has issued a CPT code (effective July 2024) for potential reimbursement of oral cavity cryotherapy devices used with chemotherapy.

InfuSystem Holdings (NYSE American: INFU) announced its participation in Lake Street Capital Markets' 8th Annual Best Ideas Growth (BIG8) Conference on September 12, 2024, at The Yale Club in New York City. CEO Richard DiIorio and CFO Barry Steele will be available for one-on-one and group meetings with investors throughout the day.

InfuSystem is a leading national health care service provider facilitating outpatient care for durable medical equipment manufacturers and health care providers. The company operates under two platforms: Patient Services (Oncology, Pain Management, and Wound Therapy) and Device Solutions (direct payer rentals, pump and consumable sales, and biomedical services).

Headquartered in Rochester Hills, Michigan, InfuSystem delivers local, field-based customer support and operates Centers of Excellence across the United States and Canada.

InfuSystem Holdings (NYSE American:INFU) reported strong Q2 2024 financial results, with record net revenues of $33.7 million, up 6% year-over-year. Key highlights include:

- Patient Services revenue increased 5% to $20.2 million
- Device Solutions revenue grew 8% to $13.5 million
- Net income rose 64.8% to $0.7 million, or $0.03 per diluted share
- Adjusted EBITDA increased 5% to $6.1 million
- Net operating cash flow up 17% to $2.7 million

The company reaffirmed its full-year 2024 guidance, projecting high-single-digit revenue growth and Adjusted EBITDA margin in the high-teens. InfuSystem's CEO highlighted the company's strategic partnerships and diversification efforts, including a new distribution agreement with Smith+Nephew.

InfuSystem Holdings, Inc. (NYSE American: INFU) has announced a three-year distribution agreement with Smith+Nephew for its negative pressure wound therapy (NPWT) system. InfuSystem will offer Smith+Nephew's advanced RENASYS◊ EDGE NPWT system, a lightweight and compact option for home-based care of chronic wounds.

The partnership leverages InfuSystem's Patient Services platform and network of over 800 in-network health insurance providers, covering 96% of the U.S. population. This collaboration aims to increase patient access to the RENASYS EDGE technology and create new revenue opportunities for both companies.

InfuSystem's CEO, Richard DiIorio, emphasized the company's ability to provide customized solutions and high-value services around partners' products, making them an attractive secondary distribution partner for Smith+Nephew's NPWT system.

InfuSystem Holdings, Inc. (NYSE American: INFU), a leading national health care service provider, has announced it will release its second quarter 2024 financial results on Thursday, August 8, 2024, before the market opens. The company will host a conference call at 9:00 a.m. Eastern Time on the same day to discuss the results.

InfuSystem operates under a two-platform model: Patient Services, which includes Oncology, Pain Management, and Wound Therapy businesses, and Device Solutions, which supports Patient Services and focuses on direct payer clients. The company provides outpatient care solutions for durable medical equipment manufacturers and health care providers, with a focus on clinic-to-home healthcare for complex treatments.

InfuSystem will present at the Sidoti Small Cap Virtual Investor Conference on June 12, 2024, at 8:30 a.m. Eastern Time. The conference will feature presentations from CEO Richard DiIorio, CFO Barry Steele, and COO Carrie Lachance. Investors can access the live webcast and replay on InfuSystem's website. Additionally, the management will host virtual one-on-one meetings throughout the day. InfuSystem, based in Rochester Hills, Michigan, provides outpatient care for durable medical equipment through two main platforms: Patient Services and Device Solutions. The company operates several Centers of Excellence in the USA and Canada.

InfuSystem, a national healthcare service provider, announced a $20 million stock repurchase program authorized by its Board of Directors. This program extends through June 30, 2026, and replaces the previous authorization expiring June 30, 2024, under which 550 thousand shares were repurchased for $6.2 million. The new program highlights confidence in the company’s operations, financial strength, and future outlook, allowing flexible share repurchases under favorable conditions. CEO Richard DiIorio emphasized the company’s commitment to strategic investments for sustainable growth while considering opportunistic buybacks.

InfuSystem reported record net revenues of $32.0 million in the first quarter of 2024, representing a 5% growth from the prior year. The gross profit increased by 10%, with a gross margin of 51.5%. Adjusted EBITDA decreased by 9% compared to the prior year. The company's liquidity totaled $45.4 million as of March 31, 2024.

InfuSystem Holdings, Inc. (NYSE American: INFU) will report first quarter 2024 financial results on May 9, 2024. The company will conduct a conference call at 9:00 a.m. Eastern Time to discuss the results. InfuSystem is a leading national health care service provider, offering outpatient care for durable medical equipment manufacturers and health care providers.